Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 5/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23720055 | 0.80 | CYP3A4 (0.45) | AOC3NISCHCHKA | |
| SCHEMBL27502154 | 0.79 | ABAT (0.41) | LOXL2TAAR1CHKAKLKB1 | |
| SCHEMBL29556362 | 0.79 | POLB (0.44) | AOC3TAAR1CHKA | |
| SCHEMBL4572683 | 0.79 | POLB (0.44) | AOC3TAAR1CHKA | |
| SCHEMBL28597260 | 0.77 | POLB (0.43) | AOC3TAAR1CHKA | |
| SCHEMBL185872 | 0.77 | LOXL2 (0.54) | AOC3LOXL2TAAR1CHKA | |
| SCHEMBL955403 | 0.73 | LMNA (0.33) | AOC3TAAR1NISCHCHKA | |
| SCHEMBL28547168 | 0.71 | MCOLN3 (0.49) | PNMTCHKA | |
| SCHEMBL23702621 | 0.70 | KMT2A (0.50) | — | |
| SCHEMBL27502153 | 0.68 | ABAT (0.67) | LOXL2TAAR1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AOC3 2261/4885LOXL2 4199/4885PNMT 3039/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AOC3 2261/4885LOXL2 4199/4885PNMT 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.